Skip to main content
Fig. 5 | BMC Pharmacology and Toxicology

Fig. 5

From: Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

Fig. 5

a Trial sequential analysis for MACE in patients receiving GLP1R agonists versus placebo; b Funnel plots showing the trajectory of the overall point estimates and their corresponding precision evolve as each study enter the meta-analysis. CI, confidence interval; GLP1R, glucagon-like peptide–1 receptor; HR, hazard ratio; MACE: major adverse cardiovascular event

Back to article page